Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay

被引:34
作者
Kopatz, Wil F. [1 ]
Brinkman, Herm Jan M. [2 ]
Meijers, Joost C. M. [1 ,2 ]
机构
[1] Univ Amsterdam, Amsterdam UMC, Dept Expt Vasc Med, Amsterdam Cardiovasc Sci, Meibergdreef 9, Amsterdam, Netherlands
[2] Sanquin Res, Dept Mol & Cellular Hemostasis, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands
关键词
Thrombin generation assay; Direct oral anticoagulants; DOAC adsorbent; Dabigatran; Rivaroxaban; Edoxaban; Apixaban; PROTHROMBIN COMPLEX CONCENTRATE; DIRECT ORAL ANTICOAGULANTS; HEALTHY-VOLUNTEERS; COAGULATION TESTS; DABIGATRAN; REVERSAL; RIVAROXABAN; PLASMA; APPLICABILITY; ANTIDOTE;
D O I
10.1016/j.thromres.2018.08.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Calibrated automated thrombography (CAT) is useful in monitoring the anticoagulant status of patients treated with direct oral anticoagulants (DOACs). This as well as other applications of the CAT are hampered by the wide inter-individual variation, making the diagnosis of the anticoagulant status of a patient on DOAC difficult when using normal pooled plasma as a reference. With dabigatran, the CAT is further hampered, as this direct thrombin inhibitor also inhibits the calibrator that is used in CAT. In this study we examined the added value of the universal DOAC adsorbent DOAC Stop in CAT. For this, we used normal pooled plasma spiked with apixaban, dabigatran, edoxaban or rivaroxaban, and performed CAT with 5 pM tissue factor. DOAC Stop effectively removed DOACs from plasma, leaving the DOAC Stop-treated plasma slightly more procoagulant compared to sham treated, non-anticoagulated plasma. Examining levels of natural coagulation inhibitors revealed a slight reduction in tissue factor pathway inhibitor upon DOAC Stop treatment. When DOAC Stop-treated plasma was used in the calibrator wells, normal unaffected calibration curves were observed, even when dabigatran was present. In conclusion, DOAC Stop can be used to abolish dabigatran influences of anticoagulated plasma when used in the calibrator wells. Also, the anticoagulant status of a DOAC treated patient can be diagnosed simply by comparing untreated plasma with the same plasma sample treated with DOAC Stop. Using this approach, a minor DOAC-independent increase in CAT response in the DOAC Stop-treated sample should be taken into account.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 29 条
[1]   Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review [J].
Adcock, D. M. ;
Gosselin, R. .
THROMBOSIS RESEARCH, 2015, 136 (01) :7-12
[2]   Global assays and the management of oral anticoagulation [J].
Brinkman H.J.M. .
Thrombosis Journal, 13 (1)
[3]   In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers [J].
Cheung, Y. W. ;
Barco, S. ;
Hutten, B. A. ;
Meijers, J. C. M. ;
Middeldorp, S. ;
Coppens, M. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (10) :1799-1805
[4]   Thrombin generation in plasma of healthy adults and children: Chromogenic versus fluorogenic thrombogram analysis [J].
Devreese, Katrien ;
Wijns, Walter ;
Combes, Isabelle ;
Van kerckhoven, Soetkin ;
Hoylaerts, Marc F. .
THROMBOSIS AND HAEMOSTASIS, 2007, 98 (03) :600-613
[5]   In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban [J].
Dinkelaar, J. ;
Molenaar, P. J. ;
Ninivaggi, M. ;
de Laat, B. ;
Brinkman, H. J. M. ;
Leyte, A. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 (06) :1111-1118
[6]   Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate [J].
Dinkelaar, Jasper ;
Patiwael, Sanne ;
Harenberg, Job ;
Leyte, Anja ;
Brinkman, Herm Jan M. .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (11) :1615-1623
[7]   Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].
Eerenberg, Elise S. ;
Kamphuisen, Pieter W. ;
Sijpkens, Meertien K. ;
Meijers, Joost C. ;
Buller, Harry R. ;
Levi, Marcel .
CIRCULATION, 2011, 124 (14) :1573-1579
[8]   Idarucizumab The Antidote for Reversal of Dabigatran [J].
Eikelboom, John W. ;
Quinlan, Daniel J. ;
van Ryn, Joanne ;
Weitz, Jeffrey I. .
CIRCULATION, 2015, 132 (25) :2412-2422
[9]   Simple method for removing DOACs from plasma samples [J].
Exner, T. ;
Michalopoulos, N. ;
Pearce, J. ;
Xavier, R. ;
Ahuja, M. .
THROMBOSIS RESEARCH, 2018, 163 :117-122
[10]   Evaluation of dabigatran, rivaroxaban and apixaban target-specific assays in a multicenter French study [J].
Gouin-Thibault, Isabelle ;
Freyburger, Genevieve ;
de Maistre, Emmanuel ;
Susen, Sophie ;
Delavenne, Xavier ;
Golmard, Jean-Louis ;
Gruel, Yves ;
Sie, Pierre ;
Abecassis, Line ;
Aillaud, Marie-Francoise ;
Ajzenberg, Nadine ;
Alhenc-Gelas, Martine ;
Flory, Anny Appert ;
Bauters, Anne ;
Biron, Christine ;
Berruyer, Micheline ;
Jouvan, Florence Blanc ;
Brionne-Francois, Marie ;
d'Audigier, Clement ;
Delahousse, Benedicte ;
Donnard, Magalie ;
Eschwege, Valerie ;
Fischer, Florence ;
Flaujac, Claire ;
Fontana, Pierre ;
Galinat, Hubert ;
Hezard, Nathalie ;
Huisse, Marie-Genevieve ;
Le Cam-Duchez, Veronique ;
Le Flem, Lena ;
Le Querrec, Agnes ;
Marlu, Raphael ;
Martin-Toutain, Isabelle ;
Meley, Roland ;
Menard-Deroure, Fanny ;
Meraud-Vialon, Geraldine ;
Mourey, Guillaume ;
Pineau-Vincent, Fabienne ;
Sauget, Pauline ;
Toussaint-Hacquard, Marie ;
Trichet, Catherine ;
Voisin, Sophie .
THROMBOSIS RESEARCH, 2017, 158 :126-133